CHICAGO, April 22, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that Vijay B. Samant, the company's President and Chief Executive Officer, will participate in a panel discussion on recent developments in cancer immunotherapy at the Biotechnology Industry Organization (BIO) International Convention (Chicago – April 22 - 25). The panel, "Fly Me to the Immune: Advances in Cancer Immunotherapy," is scheduled for Monday, April 22, 2013, from 3:45 p.m. to 5:00 p.m. CT.
Vical is developing Allovectin®, an investigational immunotherapy being evaluated initially in patients with metastatic melanoma. The company's multinational, pivotal Phase 3 trial, initiated in January 2007, is evaluating Allovectin® as first-line therapy in patients with Stage III or IV recurrent metastatic melanoma. Vical completed enrollment in February 2010 of 390 chemo-naive patients randomized on a 2:1 basis: 260 for treatment with Allovectin® and 130 for treatment with physician's choice of either dacarbazine or temozolomide. The company is projecting completion of the Phase 3 trial in mid-2013.
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Risks and uncertainties include whether Vical or others will continue developing Allovectin®; whether the Allovectin® Phase 3 trial will be completed in mid-2013, if at all; whether Allovectin® will be approved as first-line treatment for metastatic melanoma in the United States or any other countries; whether Allovectin® will be successfully developed and commercialized; whether any product candidates will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT: Alan R. Engbring (858) 646-1127 Website: www.vical.com